% IMPORTANT: The following is UTF-8 encoded. This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.
@ARTICLE{Haehl:169198,
author = {E. Haehl$^*$ and A. Rühle$^*$ and R. Klink$^*$ and T.
Kalckreuth$^*$ and T. Sprave$^*$ and E. Gkika$^*$ and C.
Zamboglou$^*$ and F. Meiß and A.-L. Grosu$^*$ and N.
Nicolay$^*$},
title = {{T}he value of primary and adjuvant radiotherapy for
cutaneous squamous cell carcinomas of the head-and-neck
region in the elderly.},
journal = {Radiation oncology},
volume = {16},
number = {1},
issn = {1748-717X},
address = {London},
publisher = {BioMed Central},
reportid = {DKFZ-2021-01322},
pages = {105},
year = {2021},
note = {#LA:E055#},
abstract = {To examine treatment patterns, oncological outcomes and
toxicity rates in elderly patients receiving radiotherapy
for cutaneous squamous cell carcinoma (cSCC) of the
head-and-neck region.In this retrospective single-center
analysis, locoregional control (LRC), progression-free
survival (PFS) and overall survival (OS) of elderly patients
> 65 years with cSCC of the head-and-neck region undergoing
radiotherapy between 2010 and 2019 were calculated. The
prognostic value of clinicopathological parameters on
radiotherapy outcomes was analyzed using the Cox
proportional hazards model. In addition, both acute and
chronic toxicities were retrospectively quantified according
to CTCAE version 5.0.A total of 69 elderly patients with
cSCC of the head-and-neck region with a median age of
85 years were included in this analysis, of whom $21.7\%$
(15 patients) presented with nodal disease. The majority of
patients exhibited a good performance status, indicated by a
median Karnofsky performance status (KPS) and Charlson
Comorbidity Index (CCI) of $80\%$ and 6 points,
respectively. Radiotherapy was administered as primary
$(48\%),$ adjuvant $(32\%)$ or palliative therapy $(20\%).$
55 patients $(79.7\%)$ completed treatment and received the
scheduled radiotherapy dose. Median EQD2 radiation doses
were 58.4 Gy, 60 Gy and 51.3 Gy in the definitive,
adjuvant and palliative situation, respectively. 2-year LRC,
PFS and OS ranged at $54.2\%,$ 33.5 and $40.7\%,$
respectively. Survival differed significantly between age
groups with a median OS of 20 vs. 12 months (p < 0.05) for
patients aged 65-80 or above 80 years. In the multivariate
analysis, positive lymph node status remained the only
significant prognostic factor deteriorating OS (HR 3.73, CI
1.54-9.03, p < 0.01). Interestingly, neither KPS nor CCI
impaired survival in this elderly patient cohort. Only 3
patients $(4.3\%)$ experienced acute CTCAE grade 3
toxicities, and no chronic CTCAE grade 2-5 toxicities were
observed in our cohort.Radiotherapy was feasible and
well-tolerated in this distinct population, showing the
general feasibility of radiotherapy for cSCC of the
head-and-neck region also in the older and oldest olds. The
very mild toxicities may allow for moderate dose escalation
to improve LRC.},
keywords = {Cutaneous squamous cell carcinoma (Other) / Elderly (Other)
/ Geriatric (Other) / Head-and-neck tumor (Other) /
Radiotherapy (Other)},
cin = {FR01 / E055},
ddc = {610},
cid = {I:(DE-He78)FR01-20160331 / I:(DE-He78)E055-20160331},
pnm = {315 - Bildgebung und Radioonkologie (POF4-315)},
pid = {G:(DE-HGF)POF4-315},
typ = {PUB:(DE-HGF)16},
pubmed = {pmid:34118984},
doi = {10.1186/s13014-021-01832-3},
url = {https://inrepo02.dkfz.de/record/169198},
}